Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Jetstar to Charge for Overhead Cabin Bags From February 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Telegram Restored on Apple App Store After Temporary Removal 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
NEW YORK, March 28, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of investors who purchased Kraton Corporation ("Kraton") (NYSE:KRA) securities between October 25, 2017 and February 21, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/kraton-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Kraton was transitioning customers to Brazilian-produced Cariflex even though certain customers had already rejected that product; (2) Kraton’s Brazilian-produced Cariflex was available to customers when in fact certain customers had already rejected that product; (3) Kraton lacked effective internal controls over financial reporting; and (4) as a result, Defendants’ statements about Kraton’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Kraton you have until April 27, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/kraton-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
